19th Annual Personalized Medicine Conference
Nov 13 – 14 | Dana Point, CA
The Annual Personalized Medicine Conference is designed to provide attendees with an opportunity to develop collaborative solutions to shared challenges in personalized medicine. Participants will exchange views with leading business executives, clinicians, journalists, and patient advocates in an intimate conference setting.
To learn more, visit the event webpage. Please note: Registration is required.
Marin Jukic, Filip Milosavljević, Espen Molden, Magnus Ingelman-Sundberg
Abstract
Genetic factors can, to a certain extent, successfully predict the therapeutic effects, metabolism, and adverse reactions of drugs. This research field, pharmacogenomics, is well developed in oncology and is currently expanding in psychiatry. Here, we summarize the latest development in pharmacogenomic psychiatry, where results of several recent large studies indicate a true benefit and cost-effectiveness of pre-emptive genotyping for more successful psychotherapy. However, it is apparent that we still lack knowledge of many additional heritable genetic factors of importance for explanation of the interindividual differences in response to psychiatric drugs. Thus, more effort to further develop pharmacogenomic psychiatry should be invested to achieve a broader clinical implementation.
Keywords: ADME genes; drug metabolism; personalized medicine; pharmacogenomics; psychiatric genetics
GMKB